Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments for COVID-19 Infection: A Randomized Controlled Trial for Repurposing antivirals
Medhat et al.,
Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments for COVID-19..,
Arab Journal of Gastroenterology, doi:10.1016/j.ajg.2022.04.005, NCT04498936
RCT with 77 nitazoxanide, 70 sofosbuvir/ledipasvir, and 73 SOC patients in Egypt, showing faster viral clearance with nitazoxanide and with sofosbuvir/ledipasvir. There was no mortality or progression to severe COVID-19 or ICU admission. Nitazoxanide 500mg qid for 14 days. SOC included vitamin C and zinc.
risk of no viral clearance, 55.5% lower, HR 0.44, p = 0.02, treatment 77, control 73, inverted to make HR<1 favor treatment, Cox proportional hazards.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Medhat et al., 6 May 2022, Randomized Controlled Trial, Egypt, peer-reviewed, 20 authors, study period July 2020 - October 2021, trial
NCT04498936 (history).
Abstract: Journal Pre-proofs
Original article
Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and
Efficient Treatments for COVID-19 Infection: A Randomized Controlled Tri‐
al for Repurposing antivirals
Mohamed A. Medhat, Mohamed El-Kassas, Haidi Karam-Allah, Ahmed Al
Shafie, Sherief Abd-Elsalam, Ehab Moustafa, Sahar M. Hassany, Marwa
Salama, Mohamed S. Abd Elghafar, Hamdy Sayed, Mohamed Badr, Dalia T.
Kamal, Ahmed Shamseldeen, Ashima'a Ossimi, Inas Moaz, Hossam El-deen
Esmael, Azza M. Ezz Eldin, Sameera Ezzat, Hossam Abdelghaffar, Khaled
Abdelghaffar
PII:
DOI:
Reference:
S1687-1979(22)00032-6
https://doi.org/10.1016/j.ajg.2022.04.005
AJG 649
To appear in:
Arab Journal of Gastroenterology
Received Date:
Revised Date:
Accepted Date:
13 March 2022
16 April 2022
26 April 2022
Please cite this article as: Medhat, M.A., El-Kassas, M., Karam-Allah, H., Al Shafie, A., Abd-Elsalam, S.,
Moustafa, E., Hassany, S.M., Salama, M., Abd Elghafar, M.S., Sayed, H., Badr, M., Kamal, D.T., Shamseldeen,
A., Ossimi, A., Moaz, I., El-deen Esmael, H., Ezz Eldin, A.M., Ezzat, S., Abdelghaffar, H., Abdelghaffar, K.,
Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments for COVID-19
Infection: A Randomized Controlled Trial for Repurposing antivirals, Arab Journal of Gastroenterology (2022),
doi: https://doi.org/10.1016/j.ajg.2022.04.005
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover
page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version
will undergo additional copyediting, typesetting and review before it is published in its final form, but we are
providing this version to give early visibility of the article. Please note that, during the production process, errors
may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
© 2022 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.
Title
Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments
for COVID-19 Infection: A Randomized Controlled Trial for Repurposing antivirals
Running Title
Sof/Led and Nitazoxanide for COVID-19 Treatment
Authors
Mohamed A. Medhat1*, Mohamed El-Kassas2*, Haidi Karam-Allah1, Ahmed Al Shafie2, Sherief
Abd-Elsalam3, Ehab Moustafa1, Sahar M. Hassany1, Marwa Salama3, Mohamed S. Abd
Elghafar4, Hamdy Sayed2, Mohamed Badr5, Dalia T. Kamal6, Ahmed Shamseldeen5, Ashima’a
Ossimi5, Inas Moaz7, Hossam El-deen Esmael1, Azza M. Ezz Eldin6, Sameera Ezzat7, Hossam
Abdelghaffar8, Khaled Abdelghaffar9
Affiliations
1Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University,
Assiut, Egypt
2Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt
3Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University,
Tanta, Egypt
4Anesthesia, Surgical Intensive Care and Pain Medicine Department, Faculty of Medicine, Tanta
University, Tanta, Egypt
5Critical Care Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt
6Clinical Pathology Department, Faculty of Medicine, Assiut University, Assiut, Egypt
7Epidemiology and Preventive Medicine Department, National Liver Institute, Menoufia
University, Menoufia, Egypt
8Supreme Council of University Hospitals, Egypt
9Ministry of Higher Education and..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit